Maria Estela Martinez-Escala
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, T-Cell, Cutaneous | 16 | 2024 | 30 | 4.520 |
Why?
|
| Skin Neoplasms | 16 | 2024 | 584 | 2.890 |
Why?
|
| Mycosis Fungoides | 6 | 2019 | 29 | 2.060 |
Why?
|
| Sezary Syndrome | 4 | 2024 | 12 | 1.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 699 | 0.840 |
Why?
|
| Lymphoma, T-Cell | 3 | 2022 | 55 | 0.820 |
Why?
|
| Nevus, Pigmented | 1 | 2019 | 50 | 0.620 |
Why?
|
| Depsipeptides | 1 | 2016 | 30 | 0.540 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2016 | 1 | 0.530 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2016 | 4 | 0.530 |
Why?
|
| Disease Progression | 4 | 2022 | 1493 | 0.530 |
Why?
|
| Vascular Neoplasms | 1 | 2016 | 20 | 0.530 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 92 | 0.520 |
Why?
|
| Cyproheptadine | 1 | 2015 | 10 | 0.500 |
Why?
|
| Thermosensing | 1 | 2015 | 4 | 0.500 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2015 | 15 | 0.500 |
Why?
|
| Pityriasis Lichenoides | 1 | 2014 | 1 | 0.490 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2014 | 1 | 0.490 |
Why?
|
| Urticaria | 1 | 2015 | 14 | 0.490 |
Why?
|
| Sensory Thresholds | 1 | 2015 | 55 | 0.490 |
Why?
|
| Drug Eruptions | 1 | 2015 | 34 | 0.480 |
Why?
|
| Cold Temperature | 1 | 2015 | 160 | 0.480 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 1226 | 0.450 |
Why?
|
| MicroRNAs | 1 | 2018 | 556 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 972 | 0.440 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 466 | 0.420 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 345 | 0.400 |
Why?
|
| Immunotherapy | 1 | 2018 | 693 | 0.400 |
Why?
|
| Skin | 6 | 2019 | 589 | 0.390 |
Why?
|
| Immunohistochemistry | 7 | 2016 | 1802 | 0.370 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 21 | 0.360 |
Why?
|
| Male | 24 | 2024 | 42632 | 0.340 |
Why?
|
| Panniculitis | 2 | 2022 | 10 | 0.320 |
Why?
|
| Prognosis | 6 | 2021 | 3802 | 0.320 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1558 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1413 | 0.310 |
Why?
|
| Female | 23 | 2024 | 46439 | 0.300 |
Why?
|
| Pruritus | 2 | 2018 | 29 | 0.300 |
Why?
|
| Adult | 17 | 2022 | 26742 | 0.290 |
Why?
|
| Humans | 31 | 2024 | 89760 | 0.290 |
Why?
|
| Aged | 15 | 2024 | 19280 | 0.290 |
Why?
|
| Retrospective Studies | 8 | 2022 | 9100 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 203 | 0.260 |
Why?
|
| Middle Aged | 16 | 2024 | 26129 | 0.250 |
Why?
|
| Ki-1 Antigen | 2 | 2015 | 19 | 0.250 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2015 | 111 | 0.240 |
Why?
|
| Young Adult | 7 | 2018 | 6360 | 0.230 |
Why?
|
| Child | 4 | 2019 | 7209 | 0.200 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2021 | 7 | 0.190 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2021 | 7 | 0.190 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 2025 | 0.180 |
Why?
|
| Lymphoma, Follicular | 1 | 2021 | 73 | 0.180 |
Why?
|
| Biopsy | 4 | 2016 | 1185 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2018 | 8283 | 0.160 |
Why?
|
| Ultraviolet Therapy | 1 | 2019 | 16 | 0.160 |
Why?
|
| Child, Preschool | 2 | 2017 | 3752 | 0.160 |
Why?
|
| Adolescent | 6 | 2017 | 9295 | 0.160 |
Why?
|
| Antipruritics | 1 | 2018 | 3 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 449 | 0.160 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 50 | 0.150 |
Why?
|
| Leg | 1 | 2018 | 140 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 34 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2020 | 860 | 0.150 |
Why?
|
| CD8 Antigens | 1 | 2017 | 82 | 0.150 |
Why?
|
| Oncostatin M Receptor beta Subunit | 1 | 2016 | 1 | 0.140 |
Why?
|
| Receptors, Interleukin | 1 | 2016 | 36 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 154 | 0.140 |
Why?
|
| Transcriptome | 1 | 2021 | 645 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 1601 | 0.130 |
Why?
|
| Interleukins | 1 | 2016 | 129 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1728 | 0.130 |
Why?
|
| Acrodermatitis | 1 | 2015 | 4 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2016 | 105 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 374 | 0.130 |
Why?
|
| Medical Records | 1 | 2016 | 120 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 319 | 0.130 |
Why?
|
| Dermatitis | 1 | 2015 | 34 | 0.130 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 313 | 0.130 |
Why?
|
| Epidermis | 1 | 2015 | 102 | 0.120 |
Why?
|
| Arteriovenous Malformations | 1 | 2015 | 45 | 0.120 |
Why?
|
| Granulocytes | 1 | 2015 | 38 | 0.120 |
Why?
|
| Photosensitivity Disorders | 1 | 2014 | 16 | 0.120 |
Why?
|
| Critical Pathways | 1 | 2015 | 37 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 188 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.120 |
Why?
|
| Biomarkers | 2 | 2018 | 1771 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 490 | 0.120 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 24 | 0.110 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 135 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2015 | 105 | 0.110 |
Why?
|
| Helicobacter Infections | 1 | 2014 | 37 | 0.110 |
Why?
|
| Remission Induction | 1 | 2016 | 741 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2014 | 37 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6847 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2015 | 173 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 275 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 276 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2014 | 169 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 378 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 151 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1944 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2013 | 445 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 576 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 2882 | 0.090 |
Why?
|
| Mutation | 2 | 2021 | 4167 | 0.090 |
Why?
|
| Phenotype | 1 | 2016 | 2450 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 1848 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2355 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 270 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1892 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2015 | 4328 | 0.070 |
Why?
|
| Time Factors | 1 | 2015 | 5346 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 1599 | 0.050 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2021 | 16 | 0.050 |
Why?
|
| Oncogenes | 1 | 2021 | 98 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 162 | 0.050 |
Why?
|
| Pharmacovigilance | 1 | 2020 | 3 | 0.050 |
Why?
|
| Hydrochlorothiazide | 1 | 2020 | 41 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 417 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2018 | 16 | 0.040 |
Why?
|
| Emollients | 1 | 2018 | 3 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2018 | 18 | 0.040 |
Why?
|
| Amines | 1 | 2018 | 28 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2018 | 21 | 0.040 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2018 | 11 | 0.040 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2018 | 35 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 2643 | 0.040 |
Why?
|
| Immune Evasion | 1 | 2018 | 35 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2018 | 85 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2018 | 237 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1050 | 0.040 |
Why?
|
| Naltrexone | 1 | 2018 | 137 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2018 | 215 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 161 | 0.030 |
Why?
|
| World Health Organization | 1 | 2017 | 108 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 787 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2886 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 278 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1370 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1281 | 0.030 |
Why?
|
| Erythema | 1 | 2015 | 29 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 71 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 70 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 754 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 217 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 777 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 210 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 233 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2015 | 88 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2018 | 466 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2015 | 152 | 0.030 |
Why?
|
| Hashimoto Disease | 1 | 2014 | 11 | 0.030 |
Why?
|
| Sjogren's Syndrome | 1 | 2014 | 34 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2014 | 83 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 864 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 977 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 212 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 691 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 922 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 891 | 0.020 |
Why?
|
| Carcinoma | 1 | 2015 | 443 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1910 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1876 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 951 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1864 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 11814 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 3400 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 5522 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 27456 | 0.010 |
Why?
|
| Neoplasms | 1 | 2014 | 3082 | 0.010 |
Why?
|